Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 651

1.

GUROPA survey: genito-urinary radiation oncology prescription attitudes.

Fersino S, Arcangeli S, Jereczek-Fossa BA, D'Angelillo R, Bertoni F, D'Agostino GR, Triggiani L, Corvò R, Magrini SM, Alongi F; on the behalf of AIRO.

Radiol Med. 2018 Jul 13. doi: 10.1007/s11547-018-0918-z. [Epub ahead of print]

PMID:
30006764
2.

Pixantrone: novel mode of action and clinical readouts.

Minotti G, Han H, Cattan V, Egorov A, Bertoni F.

Expert Rev Hematol. 2018 Jul;11(7):587-596. doi: 10.1080/17474086.2018.1476848. Epub 2018 Jun 18.

PMID:
29912583
3.

Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study.

Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S; Pros-IT CNR study group.

Health Qual Life Outcomes. 2018 Jun 13;16(1):122. doi: 10.1186/s12955-018-0952-5.

4.

Recent advances in understanding the biology of marginal zone lymphoma.

Bertoni F, Rossi D, Zucca E.

F1000Res. 2018 Mar 28;7:406. doi: 10.12688/f1000research.13826.1. eCollection 2018. Review.

5.

Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.

Spriano F, Chung EY, Panini N, Cascione L, Rinaldi A, Erba E, Stathis A, D'Incalci M, Bertoni F, Gatta R.

Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15212. [Epub ahead of print] No abstract available.

PMID:
29611184
6.

Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.

Gerber B, Manzoni M, Spina V, Bruscaggin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A.

Haematologica. 2018 Jun;103(6):e245-e248. doi: 10.3324/haematol.2017.184358. Epub 2018 Feb 22. No abstract available.

7.

Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides.

Bergmann TJ, Fregno I, Fumagalli F, Rinaldi A, Bertoni F, Boersema PJ, Picotti P, Molinari M.

J Biol Chem. 2018 Apr 13;293(15):5600-5612. doi: 10.1074/jbc.RA117.001484. Epub 2018 Feb 16.

PMID:
29453283
8.

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.

Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D.

Blood. 2018 May 31;131(22):2413-2425. doi: 10.1182/blood-2017-11-812073. Epub 2018 Feb 15.

PMID:
29449275
9.

Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.

Restelli V, Lupi M, Vagni M, Chilà R, Bertoni F, Damia G, Carrassa L.

Target Oncol. 2018 Apr;13(2):235-245. doi: 10.1007/s11523-018-0553-6.

PMID:
29441438
10.

IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.

Bandini C, Pupuleku A, Spaccarotella E, Pellegrino E, Wang R, Vitale N, Duval C, Cantarella D, Rinaldi A, Provero P, Di Cunto F, Medico E, Bertoni F, Inghirami G, Piva R.

Cancers (Basel). 2018 Jan 18;10(1). pii: E21. doi: 10.3390/cancers10010021.

11.

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

Chen J, Guccini I, Mitri DD, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A.

Nat Genet. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15.

12.

BET Proteins as Targets for Anticancer Treatment.

Stathis A, Bertoni F.

Cancer Discov. 2018 Jan;8(1):24-36. doi: 10.1158/2159-8290.CD-17-0605. Epub 2017 Dec 20. Review.

PMID:
29263030
13.

ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration.

Puddinu V, Casella S, Radice E, Thelen S, Dirnhofer S, Bertoni F, Thelen M.

Oncotarget. 2017 Jun 29;8(49):85068-85084. doi: 10.18632/oncotarget.18844. eCollection 2017 Oct 17.

14.

Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR.

Gacci M, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S; Pros-IT CNR study group.

Eur Urol Focus. 2017 Oct;3(4-5):321-324. doi: 10.1016/j.euf.2017.10.009. Epub 2017 Nov 13.

PMID:
29146557
15.

Application of chitosan in removal of molybdate ions from contaminated water and groundwater.

Bertoni FA, González JC, García SI, Sala LF, Bellú SE.

Carbohydr Polym. 2018 Jan 15;180:55-62. doi: 10.1016/j.carbpol.2017.10.027. Epub 2017 Oct 6.

PMID:
29103521
16.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.

Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24.

PMID:
29066507
17.

TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line.

Gaudio E, Paduano F, Pinton S, D'Agostino S, Rocca R, Costa G, Ngankeu A, Aqeilan RI, Croce CM, Bertoni F, Alcaro S, Trapasso F.

Br J Haematol. 2017 Oct 19. doi: 10.1111/bjh.14989. [Epub ahead of print] No abstract available.

PMID:
29048125
18.

Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.

Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, Nolè F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D'Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E; GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group.

Ann Oncol. 2017 Sep 1;28(9):2206-2212. doi: 10.1093/annonc/mdx299.

PMID:
28911070
19.

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.

Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP.

Nat Med. 2017 Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14.

20.

Let's give BACH2 a breath of fresh air.

Bertoni F.

Blood. 2017 Aug 10;130(6):696-697. doi: 10.1182/blood-2017-06-790402. No abstract available.

PMID:
28798058
21.

PCSF: An R-package for network-based interpretation of high-throughput data.

Akhmedov M, Kedaigle A, Chong RE, Montemanni R, Bertoni F, Fraenkel E, Kwee I.

PLoS Comput Biol. 2017 Jul 31;13(7):e1005694. doi: 10.1371/journal.pcbi.1005694. eCollection 2017 Jul.

22.

Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.

Cascione L, Rinaldi A, Chiappella A, Kwee I, Ciccone G, Altenbuchinger M, Kohler C, Vitolo U, Inghirami G, Bertoni F.

Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14817. [Epub ahead of print] No abstract available.

PMID:
28737236
23.

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.

Bernasconi E, Gaudio E, Lejeune P, Tarantelli C, Cascione L, Kwee I, Spriano F, Rinaldi A, Mensah AA, Chung E, Stathis A, Siegel S, Schmees N, Ocker M, Zucca E, Haendler B, Bertoni F.

Br J Haematol. 2017 Sep;178(6):936-948. doi: 10.1111/bjh.14803. Epub 2017 Jun 27.

PMID:
28653353
24.

p16 protein expression and correlation with clinical and pathological features in osteosarcoma of the jaws: Experience of 37 cases.

Asioli S, Righi A, Rucci P, Tarsitano A, Marchetti C, Bacchini P, Balbi T, Bertoni F, Foschini MP.

Head Neck. 2017 Sep;39(9):1825-1831. doi: 10.1002/hed.24835. Epub 2017 May 31.

PMID:
28560748
25.

Methylation patterns in marginal zone lymphoma.

Arribas AJ, Bertoni F.

Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):24-31. doi: 10.1016/j.beha.2016.09.003. Epub 2016 Nov 5. Review.

PMID:
28288713
26.

Pros-IT CNR: an Italian prostate cancer monitoring project.

Noale M, Maggi S, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Maurizi Enrici R, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Tubaro A, Zagonel V, Zattoni F, Crepaldi G; Pros-IT CNR study group.

Aging Clin Exp Res. 2017 Apr;29(2):165-172. doi: 10.1007/s40520-017-0735-6. Epub 2017 Feb 24.

PMID:
28236267
27.

Dnmt3a restrains mast cell inflammatory responses.

Leoni C, Montagner S, Rinaldi A, Bertoni F, Polletti S, Balestrieri C, Monticelli S.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1490-E1499. doi: 10.1073/pnas.1616420114. Epub 2017 Feb 6.

28.

Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.

Bujisic B, De Gassart A, Tallant R, Demaria O, Zaffalon L, Chelbi S, Gilliet M, Bertoni F, Martinon F.

Blood. 2017 Apr 27;129(17):2420-2428. doi: 10.1182/blood-2016-09-741348. Epub 2017 Feb 6.

29.

Staining the target: CD37 expression in lymphomas.

Bertoni F, Stathis A.

Blood. 2016 Dec 29;128(26):3022-3023. doi: 10.1182/blood-2016-11-748137. No abstract available.

30.

Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.

Restelli V, Vagni M, Arribas AJ, Bertoni F, Damia G, Carrassa L.

Br J Haematol. 2018 Apr;181(1):129-133. doi: 10.1111/bjh.14506. Epub 2016 Dec 26. No abstract available.

PMID:
28025833
31.

Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.

Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, D'Antuono R, Pinton S, Losa M, Gnetti L, Arribas A, Fraering P, Bertoni F, Nepveu A, Alimonti A.

Nat Commun. 2016 Dec 12;7:13719. doi: 10.1038/ncomms13719.

32.

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

Vázquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K, Erba E, Panini N, Rinaldi A, Kwee I, Beltrame L, Bekradda M, Cvitkovic E, Bertoni F, Frapolli R, D'Incalci M.

Oncotarget. 2017 Jan 31;8(5):7598-7613. doi: 10.18632/oncotarget.13814.

33.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D'Incalci M, Noel K, Cvitkovic E, Raymond E, Bertoni F.

Oncotarget. 2016 Dec 20;7(51):84675-84687. doi: 10.18632/oncotarget.13181.

34.

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F, Inghirami G; AIRC 5xMille Consortium ‘Genetics-Driven Targeted Management of Lymphoid Malignancies’.

Oncotarget. 2016 Nov 29;7(48):79637-79653. doi: 10.18632/oncotarget.12876.

35.

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.

Gaudio E, Tarantelli C, Ponzoni M, Odore E, Rezai K, Bernasconi E, Cascione L, Rinaldi A, Stathis A, Riveiro E, Cvitkovic E, Zucca E, Bertoni F.

Oncotarget. 2016 Sep 6;7(36):58142-58147. doi: 10.18632/oncotarget.10983.

36.

Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Pizzi M, Boi M, Bertoni F, Inghirami G.

Leukemia. 2016 Sep;30(9):1805-15. doi: 10.1038/leu.2016.161. Epub 2016 Jun 8. Review.

PMID:
27389058
37.

The genetics of nodal marginal zone lymphoma.

Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbò F, Zairis S, Diop F, Cerri M, Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B, Inghirami G, Bertoni F, Foà R, Rabadan R, Gaidano G, Rossi D.

Blood. 2016 Sep 8;128(10):1362-73. doi: 10.1182/blood-2016-02-696757. Epub 2016 Jun 22.

38.

The genetic landscape of dural marginal zone lymphomas.

Ganapathi KA, Jobanputra V, Iwamoto F, Jain P, Chen J, Cascione L, Nahum O, Levy B, Xie Y, Khattar P, Hoehn D, Bertoni F, Murty VV, Pittaluga S, Jaffe ES, Alobeid B, Mansukhani MM, Bhagat G.

Oncotarget. 2016 Jul 12;7(28):43052-43061. doi: 10.18632/oncotarget.9678.

39.

Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines.

Bernasconi E, Gaudio E, Kwee I, Bertoni F.

Methods Mol Biol. 2016;1436:305-12. doi: 10.1007/978-1-4939-3667-0_20.

PMID:
27246223
40.

Ameloblastic Fibrosarcoma of the mandible evolving from a prior Ameloblastic Fibroma after two years: an unusual finding.

Bertoni F, Del Corso G, Bacchini P, Marchetti C, Tarsitano A.

Int J Surg Pathol. 2016 Oct;24(7):656-9. doi: 10.1177/1066896916646448. Epub 2016 Apr 28.

PMID:
27130840
41.

The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance.

Zucca E, Bertoni F.

Blood. 2016 Apr 28;127(17):2082-92. doi: 10.1182/blood-2015-12-624304. Epub 2016 Mar 17. Review.

42.

Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.

Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, Ponzoni M, Cascione L, Targa A, Stathis A, Goodstal S, Zucca E, Bertoni F.

Ann Oncol. 2016 Jun;27(6):1123-8. doi: 10.1093/annonc/mdw131. Epub 2016 Mar 8.

PMID:
26961147
43.

Radiosurgery Using Tomotherapy for Patients with Brain Oligo-metastasis: A Retrospective Analysis on Feasibility and Tolerance.

Bruni A, Gaito S, Ciarmatori A, Lanfranchi B, Mazzeo E, Maffei N, Giacobazzi P, Turco E, Guidi G, Bertoni F.

Anticancer Res. 2015 Dec;35(12):6805-12.

PMID:
26637900
44.

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.

Scarfò I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti R, Circosta P, Abate F, Barreca A, Novero D, Mathew S, Rinaldi A, Tiacci E, Serra S, Deaglio S, Neri A, Falini B, Rabadan R, Bertoni F, Inghirami G, Piva R; European T-Cell Lymphoma Study Group.

Blood. 2016 Jan 14;127(2):221-32. doi: 10.1182/blood-2014-12-614503. Epub 2015 Oct 13.

45.

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma.

Ferretti E, Di Carlo E, Ognio E, Guarnotta C, Bertoni F, Corcione A, Prigione I, Fraternali-Orcioni G, Ribatti D, Ravetti JL, Ponzoni M, Tripodo C, Pistoia V.

Oncoimmunology. 2015 Jun 19;4(10):e1030560. eCollection 2015 Oct.

46.

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954.

47.

Paediatric chondrosarcomas: a retrospective review of 17 cases.

Gambarotti M, Righi A, Picci P, Bertoni F, Manfrini M, Donati DM, Dei Tos AP, Vanel D.

Histopathology. 2016 Jun;68(7):1073-8. doi: 10.1111/his.12881. Epub 2015 Nov 25.

PMID:
26408960
48.

Histologic transformation in marginal zone lymphomas†.

Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia AA, Bertoni F, Ramponi A, Mazzucchelli L, Cavalli F, Gaidano G, Zucca E.

Ann Oncol. 2015 Nov;26(11):2329-35. doi: 10.1093/annonc/mdv368. Epub 2015 Sep 23.

PMID:
26400898
49.

Life expectancy of young adults with follicular lymphoma.

Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F, Moccia A, Rancoita PM, Gribben J, Cavalli F, Gaidano G, Lister TA, Montserrat E, Ghielmini M, Zucca E.

Ann Oncol. 2015 Nov;26(11):2317-22. doi: 10.1093/annonc/mdv376. Epub 2015 Sep 11.

PMID:
26362567
50.

The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models.

Bernasconi E, Gaudio E, Kwee I, Rinaldi A, Cascione L, Tarantelli C, Mensah AA, Stathis A, Zucca E, Vesci L, Giannini G, Bertoni F.

Br J Haematol. 2015 Nov;171(3):378-86. doi: 10.1111/bjh.13595. Epub 2015 Aug 3.

PMID:
26235926

Supplemental Content

Loading ...
Support Center